Unicycive Therapeutics, Inc. (UNCY) stock
Close on Nov 13, 2026Market cap $98.89MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $98.89M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 1.86
- Dividend yield
- –
- Free cash flow yield
- -28.16%
Fundamentals
- Net income
- -$36.21M
- EPS, diluted
- -$1.67
- Free cash flow
- -$29.35M
- Book value per share
- $1.86
- Diluted shares
- 28M
Trading
- Next earnings
- Q3 FY2026, expected soon
- Previous close
- $3.64
- Open
- $3.63
- Day's range
- $3.52 – $3.69
- Volume
- 690,182
- Average volume (20 days)
- 1,058,869
- Index membership
- Russell 2000 (since Jun 2026)
- Beta (5 years)
- -0.80
- 52-week range
- $3.33 – $8.74
- RSI (14 days)
- 41.7
- Volatility (1 year)
- 78.7%
- Relative volume
- 0.76×
- WACC
- 7.6%
On 1 of our idea list: More cash than they're worth
Index membership is inferred from the holdings of funds that track each index (IWM), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | UNCY | S&P 500 | Difference | UNCY per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -4.8% | -3.0% | −1.8 pts | ||
| 3 months | -34.3% | -2.8% | −31.5 pts | ||
| Year to date | -38.5% | +11.5% | −50.0 pts | ||
| 1 year | -33.4% | +13.5% | −46.9 pts | ||
| 3 years | -34.3% | +77.7% | −112.0 pts | -13.1% | +21.1% |
| 5 years | -86.9% | +72.6% | −159.5 pts | -33.4% | +11.5% |
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Unicycive Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- News
- Results
- Results
- Results
- Results
- Results
About Unicycive Therapeutics
Pharmaceutical Preparations
Unicycive Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing and commercializing therapies for kidney diseases and other medical conditions. The company's pipeline includes two primary therapeutic candidates: oxylanthanum carbonate, a nanoparticle lanthanum-based phosphate binder designed for treating hyperphosphatemia in chronic kidney disease patients on dialysis, and UNI-494, a drug candidate under development for acute kidney injury. Unicycive operates by licensing drug technologies from other pharmaceutical entities to advance them through clinical development, regulatory approval, and commercialization. Target populations include chronic kidney disease patients suffering from elevated phosphate levels and individuals with sudden kidney injury.
Company profile, executives and historyUnicycive Therapeutics stock: common questions
What is Unicycive Therapeutics's stock price?
UNCY closed at $3.55 on Nov 13, 2026, down 2.47% on the day. Over the past 52 weeks it traded between $3.33 and $8.74.
What is Unicycive Therapeutics's market cap?
Unicycive Therapeutics was worth $98.89M at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
What is UNCY's P/E ratio?
Unicycive Therapeutics lost money over fiscal 2025 (diluted EPS -$1.67), so it has no meaningful P/E ratio.
Does Unicycive Therapeutics pay a dividend?
No. Unicycive Therapeutics has not paid a cash dividend over the last twelve months.
When does Unicycive Therapeutics report earnings next?
Unicycive Therapeutics's Q3 FY2026 results are due soon; the company has not yet filed them with the SEC.
How has UNCY stock performed over the past year?
Including dividends, UNCY returned -33.4% over the past year, against +13.5% for the S&P 500.
How many UNCY shares are sold short?
5M shares were sold short at the latest FINRA report, 24.38% of the float, or 4.2 days of average trading volume.
Who are Unicycive Therapeutics's competitors?
Companies most similar to Unicycive Therapeutics by business, industry and size include AKBA, TVTX, XRTX, ARDX, RARE.
See a number that looks wrong?